Join the Oncology Voice Network. Join for Free
Professional Medical Writer Assistance in Oncology Clinical Trials
PMW usage phase III oncology trials professional medical writer assistance

Professional Medical Writer Assistance in Oncology Clinical Trials


Share This Article


Summary

  • The use of professional medical writers (PMWs) in oncologic phase III randomized controlled trials (RCTs) has been historically low, but recent data on their usage is limited.
  • This study aimed to quantify the usage of PMWs in cancer-specific phase III RCTs by analyzing trial manuscripts on ClinicalTrials.gov.
  • Out of 600 trials, 260 (43.3%) involved PMWs in writing the trial manuscript.
  • Industry-funded trials were significantly more likely to use PMWs compared to nonindustry trials (54.9% vs. 3.0%, p < .001).
  • PMW usage was higher in trials that met their primary endpoint (53.4% vs. 32.9%, p < .001) and those resulting in FDA approval (63.1% vs. 36.3%, p < .001).
  • Among treatment interventions, PMW use was most prevalent in systemic therapy trials (50.2%).
  • The study observed a significant increase in the use of PMWs over time (odds ratio: 1.11/year, p = .001).
  • The study calls for increased transparency in reporting the funding and use of PMWs.

Academic publishing remains the cornerstone of cancer research and scientific communication of clinical trials. Over the years, there has been increasing interest in the use of professional medical writers (PMWs) to help investigators improve quality of writing and/or reduce the time to publication. Use rates of such PMW services have historically been low, but contemporary data regarding PMW usage remain scarce. With an increasing role of industry sponsorship in cancer clinical trials, we sought to characterize the rate of PMW use among reports of phase III cancer clinical trial results, focusing on factors associated with PMW usage.

Click for Source Download PDF version
PMW usage, phase III oncology trials, professional medical writer assistance

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN